EFFECT OF HIV INFECTION AND ITS TREATMENT ON KIDNEY FUNCTION IN THE AIDS COHORT

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 多中心艾滋病队列研究的目的（MACS旨在阐明男男性行为者感染人类免疫缺陷病毒1型（HIV-1）的自然史，包括：1）在人群水平上，高效抗逆转录病毒疗法（HAART）和MACS队列将暴露的新疗法的长期有效性; 2）个体对HAART反应的决定因素和治疗不良反应的机制，包括副作用和耐药性的发展; 3）病毒学参数的表征（包括抗原和遗传因素）、免疫应答和宿主遗传因素在进展者和非进展者中的作用，特别是因为它们可以有助于治疗性疫苗的开发; 4）进一步表征HIV-1血清阴性的高度暴露受试者中对感染的抗性的性质，特别是当它们与有效预防性疫苗的开发有关时; 5）增加在具有不同治疗使用的大群组中疾病进展的预后标志物的知识; 6）确定有助于HIV-1诱导的免疫抑制的特定结果的因素; 7）进一步阐明HIV-1相关恶性肿瘤的流行病学和发病机制。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the Multicenter AIDS Cohort Study (MACS is to elucidate the natural history of human immunodeficiency virus type 1 (HIV-1) infection in men who have sex with men, including: 1) the long term effectiveness, at the population level, of highly active antiretroviral therapy (HAART) and new therapies to which the MACS cohort will be exposed; 2) the determinants of individual responses to HAART and the mechanisms of adverse effects of treatment, including side effects and development of drug resistance; 3) characterization of virologic parameters (including antigenic and genetic factors), immune responses, and host genetic factors in progressors and non-progressors, especially as they can contribute to development of therapeutic vaccines; 4) further characterization of the nature of resistance to infection in HIV-1 seronegative highly exposed subjects, especially as they relate to development of an effective preventive vaccine; 5) increasing knowledge of prognostic markers of disease progression in a large cohort with varying use of therapies; 6) determination of factors that contribute to specific outcomes of HIV-1 induced immunosuppression; 7) further elucidation of the epidemiology and pathogenesis of HIV-1 related malignancies.